← Povetacicept
What podcasts say about Povetacicept
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Povetacicept
4 statements · 1 positive · 2 negative · 1 neutral
Vertex’s povetacicept will likely receive approval.
“I think there's very little doubt. that this drug is going to get approved.”
Open the episode · Episode 202 - November 6, 2026Listen at 16:56
Vertex has declined to disclose treatment interruptions in its study.
“Vertex has not provided that answer. They've declined. to provide an answer.”
Open the episode · Episode 202 - November 6, 2026Listen at 18:35
Vertex’s phase three study showed equal infection risk between treatment and control.
“the infection risk was equal, same between the drug arm and the control arm.”
Open the episode · Episode 202 - November 6, 2026Listen at 18:51
An IgG-monitoring label would disadvantage Vertex against competing drugs.
“that would put them at a competitive disadvantage.”
Open the episode · Episode 202 - November 6, 2026Listen at 19:21
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.